Search results for " arthritis"

showing 10 items of 629 documents

Scores for functional disability in patients with rheumatoid arthritis are correlated at higher levels with pain scores than with radiographic scores

2000

Objective To analyze correlations of functional disability scores with other measures of clinical status, in particular, Larsen radiographic scores and pain scores, in patients with rheumatoid arthritis (RA). Methods The functional capacity of 141 patients with RA (102 women, 39 men; median age 57 years; median disease duration 11.8 years; 83% rheumatoid factor positive) was assessed according to the Stanford Health Assessment Questionnaire (HAQ). Other variables studied included Larsen scores for radiographic damage of the small joints of the hands, wrists, and feet, pain scores by visual analog scale (VAS), Disease Activity Scores, general health scores by VAS, and Beck Depression Invento…

Malemusculoskeletal diseasesmedicine.medical_specialtyVisual analogue scaleRadiographyImmunologySpearman's rank correlation coefficientArthritis RheumatoidRheumatologymedicineHumansImmunology and AllergyRheumatoid factorPharmacology (medical)In patientArthrographyskin and connective tissue diseasesAgedPain Measurementbusiness.industryBeck Depression InventoryMiddle Agedmedicine.diseasehumanitiesFunctional disabilityRheumatoid arthritisPhysical therapyRegression AnalysisFemalebusinessArthritis & Rheumatism
researchProduct

Recommendations for standardization and phenotype definitions in genetic studies of osteoarthritis: the TREAT-OA consortium

2011

Objective: To address the need for standardization of osteoarthritis (OA) phenotypes by examining the effect of heterogeneity among symptomatic (SOA) and radiographic osteoarthritis (ROA) phenotypes. Methods: Descriptions of OA phenotypes of the 28 studies involved in the TREAT-OA consortium were collected. We investigated whether different OA definitions result in different association results by creating various hip OA definitions in one large population based cohort (the Rotterdam Study I (RSI)) and testing those for association with gender, age and body mass index using one-way ANOVA. For ROA, we standardized the hip-, knee- and hand ROA definitions and calculated prevalence's of RO…

Malenivelrikkomedicine.medical_specialtygenetiikkaBiomedical EngineeringMEDLINEdiagnostiset kriteeritOsteoarthritisbehavioral disciplines and activitiesArticleCohort Studies03 medical and health sciencesRotterdam Study0302 clinical medicineRheumatologyInternal medicineTREATOAOsteoarthritismedicinePrevalenceGeneticsHumansOrthopedics and Sports Medicine030304 developmental biologyRheumatology and Autoimmunity2. Zero hunger030203 arthritis & rheumatology0303 health sciencesAnalysis of Varianceperinnöllisyystiedebusiness.industryCase-control studyDefinitionReference Standardsmedicine.diseaseGenetics Osteoarthritis Phenotype Definition TREATOA genome-wide association radiographic hip osteoarthritis bone-mineral density knee osteoarthritis hand osteoarthritis osteoporotic fractures general-population joint involvement risk-factors susceptibilityRheumatology3. Good healthPhenotypeCase-Control Studiesdiagnostic criteriaCohortPhysical therapyFemalebusinessBody mass indexCohort study
researchProduct

Lifestyle Risk Factors Increase the Risk of Hospitalization for Sciatica: Findings of Four Prospective Cohort Studies

2017

BACKGROUND: The purpose of this study is to assess the effects of lifestyle risk factors on the risk of hospitalization for sciatica and to determine whether overweight or obesity modifies the effect of leisure-time physical activity on hospitalization for sciatica. METHODS: We included 4 Finnish prospective cohort studies (Health 2000 Survey, Mobile Clinic Survey, Helsinki Health Study, and Young Finns Study) consisting of 34,589 participants and 1259 hospitalizations for sciatica during 12 to 30 years of follow-up. Sciatica was based on hospital discharge register data. We conducted a random-effects individual participant data meta-analysis. RESULTS: After adjustment for confounding facto…

Maleobesityphysical activityliikuntaOverweightCohort Studies0302 clinical medicineRisk FactorsEpidemiologyMedicineProspective Studies030212 general & internal medicineta315Prospective cohort studylow back painAged 80 and over2. Zero hungereducation.field_of_studyexerciseta3141ylipainoASSOCIATIONGeneral MedicineMiddle AgedDEGENERATION3. Good healthLUMBAR DISC DISEASEFemaleSMOKING MODELmedicine.symptomRisk assessmentLumbar disc diseaseLOW-BACK-PAINhospitalizationCohort studyAdultmusculoskeletal diseasesmedicine.medical_specialtyPopulationiskiassmokingYoung Adult03 medical and health sciencestupakointiInternal medicineHumanseducationLife StyleMETAANALYSISAgedsciatica030203 arthritis & rheumatologybusiness.industryta3121Overweightmedicine.diseasenervous system diseases3141 Health care sciencePHYSICAL-ACTIVITYINTERVERTEBRAL DISCSPhysical therapylihavuusFOLLOW-UPbusinessBody mass indexThe American Journal of Medicine
researchProduct

Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry

2014

Background: Some studies have shown that switching patients from one tumor necrosis factor (TNF)-alfa inhibitor to another may be beneficial when they have an inadequate response or an adverse event. Objective: We sought to assess the variables predicting the efficacy of the second TNF-alfa inhibitor in patients discontinuing the first TNF-alfa inhibitor. Methods: Data from all 5423 consecutive patients starting TNF-alfa inhibitor therapy for psoriasis between September 2005 and September 2010 who were included in the Italian Psocare registry were analyzed. Results: In 105 patients who switched to a second TNF-alfa inhibitor who had complete follow-up data, 75% improvement in the Psoriasis …

Maleprimary inefficacy75% improvement in the Psoriasis Area Severity Index score; PASI; PASI 75; Psoriasis Area Severity Index; TNF; biologics; efficacy; primary inefficacy; psoriasis; secondary loss of efficacy; switching; tumor necrosis factor; tumor necrosis factor-alfa inhibitors; Adult; Analysis of Variance; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Cohort Studies; Confidence Intervals; Dose-Response Relationship Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Immunoglobulin G; Italy; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Proportional Hazards Models; Psoriasis; Receptors Tumor Necrosis Factor; Registries; Retrospective Studies; Risk Assessment; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha; Young AdultSWITHCESefficacyTNFpsoriasis; psoriasis arthritis; pharmachological treatmentPASI 75Severity of Illness IndexReceptors Tumor Necrosis FactorEtanerceptCohort StudiesMonoclonalReceptorsSettore MED/35 - Malattie Cutanee E VenereeRegistriesHumanizedtumor necrosis factor-alfa inhibitors.switchingHazard ratioAntibodies MonoclonalMiddle AgedTreatment OutcomeItalyPredictive value of tests75% improvement in the Psoriasis Area Severity Index scoreFemaleDrugPsoriasis Area Severity IndexbiologicTNF-alphaAdultmedicine.medical_specialtytumor necrosis factorDermatology75% improvement in the Psoriasis Area Severity Index score; PASI; PASI 75; Psoriasis Area Severity Index; TNF; biologics; efficacy; primary inefficacy; psoriasis; secondary loss of efficacy; switching; tumor necrosis factor; tumor necrosis factor-alfa inhibitorsAntibodies Monoclonal Humanizedsecondary loss of efficacyRisk AssessmentAntibodiestumor necrosis factor-alfa inhibitorsDrug Administration ScheduleDose-Response RelationshipYoung AdultSettore MED/35Predictive Value of TestsInternal medicinePsoriasisSeverity of illnessmedicineConfidence IntervalsHumansPsoriasisbiologicsAdverse effectPsoriasis; TNF-alphaProportional Hazards ModelsRetrospective Studiespsoriasibiologics; efficacy; primary inefficacy; psoriasis; secondary loss of efficacy; switching; tumor necrosis factor-alfa inhibitors; Adalimumab; Adult; Analysis of Variance; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Cohort Studies; Confidence Intervals; Dose-Response Relationship Drug; Drug Administration Schedule; Etanercept; Female; Follow-Up Studies; Humans; Immunoglobulin G; Infliximab; Italy; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Proportional Hazards Models; Psoriasis; Receptors Tumor Necrosis Factor; Registries; Retrospective Studies; Risk Assessment; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha; Young Adult; 2708Analysis of Variancepharmachological treatmentDose-Response Relationship DrugProportional hazards modelbusiness.industrytumor necrosis factor-alfa inhibitorTumor Necrosis Factor-alphaPASIAdalimumabRetrospective cohort studypsoriasis arthritismedicine.diseaseConfidence intervalInfliximabSurgeryImmunoglobulin GMultivariate AnalysisANTI-TNFAbusiness2708Follow-Up Studies
researchProduct

Validation of the Western Ontario and McMaster Universities Osteoarthritis Index in Patients Having Undergone Ankle Fracture Surgery

2019

The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) is a patient-reported outcome measure (PROM) that is widely used to evaluate the pain, stiffness, and physical function of patients with osteoarthritis of the hip and knee. Although the WOMAC has also been used for patients after foot and ankle surgery, it has not been validated for this purpose. A total of 130 patients with surgically treated ankle fractures completed the WOMAC, Visual Analogue Scale Foot and Ankle (VAS FA), Lower Extremity Functional Scale (LEFS), 15D Health-Related Quality-of-Life Questionnaire (15D), and Visual Analog Scale for General Health (VAS general health) after foot and ankle surgery. The…

MalepsychometricsVisual Analog Scalemedicine.medical_treatmentOsteoarthritisFINNISH VERSIONSeverity of Illness Index0302 clinical medicineFracture FixationQUALITY-OF-LIFESurveys and QuestionnairesFracture fixationOrthopedics and Sports MedicineProspective Studies030212 general & internal medicineOntarioPain PostoperativeINSTRUMENTMiddle Aged3. Good healthmedicine.anatomical_structureWOMACConvergent validityRELIABILITYFemaleVAS-FACOEFFICIENTmusculoskeletal diseasesmedicine.medical_specialtyWOMACUniversitiesVisual analogue scalereliability validityAnkle FracturesANALOG SCALE FOOT03 medical and health sciencesOsteoarthritisanklemedicineHumansPatient Reported Outcome MeasuresVALIDITYARTHROPLASTYRASCH ANALYSIS030203 arthritis & rheumatologybusiness.industryFoot and ankle surgeryReproducibility of Results3126 Surgery anesthesiology intensive care radiologymedicine.diseaseArthroplastySurgeryQuality of LifePhysical therapySurgeryLEFSAnklebusinessFollow-Up StudiesThe Journal of Foot and Ankle Surgery
researchProduct

Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept…

2012

Objective: To evaluate the risk of serious infections (SIs) in RA patients receiving anti-TNF therapy on the basis of the data included in the GISEA register. METHODS: The study involved 2769 adult patients with long-standing RA (mean age 53.2±13.4years; mean disease duration 9.0±8.3years) enrolled in the GISEA register, who had been treated for at least 6months with TNF inhibitors or had discontinued therapy due to SI: 837 (30%) treated with infliximab (IFN), 802 (29%) with adalimumab (ADA), and 1130 (41%) with etanercept (ETN). RESULTS: 176 patients had experienced at least one of the 226 Sis during the 9years of treatment with an anti-TNF agent, an overall incidence of 31.8/1000 patient-…

Malerheumatoid arthritisArthritisReceptors Tumor Necrosis FactorEtanerceptEtanerceptArthritis RheumatoidAdalimumab; Adult; Aged; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthritis Rheumatoid; Etanercept; Female; Humans; Immunoglobulin G; Incidence; Infection; Infliximab; Male; Middle Aged; Receptors Tumor Necrosis Factor; Registries; Tumor Necrosis FactorsRheumatoidadalimumabMonoclonalReceptorsImmunology and AllergyRegistriesinfectionsHumanizedAnti-TNF agents; GISEA register; Infections; Predictive factorsIncidence (epidemiology)IncidenceAntibodies MonoclonalAnti-TNF agentsMiddle AgedRheumatoid arthritisAntirheumatic AgentsCohortTumor Necrosis FactorsFemaleInfectionPredictive factorsmedicine.druganti-TNF; serious infections; rheumatoid arthritisAdultmedicine.medical_specialtyanti-TNF therapy; infections; rheumatoid arthritis; adalimumab; etanercept; infliximabanti-TNF therapyserious infectionsImmunologyInfections rheumatoid arthritis anti-TNF therapyAntibodies Monoclonal HumanizedInfectionsAntibodiesInternal medicinemedicineAdalimumabHumansAgedGISEA registerbusiness.industryArthritisAdalimumabanti-TNFGISEA register; Infections; Anti-TNF agents; Predictive factors; Adalimumab; Adult; Aged; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthritis Rheumatoid; Etanercept; Female; Humans; Immunoglobulin G; Incidence; Infection; Infliximab; Male; Middle Aged; Receptors Tumor Necrosis Factor; Registries; Tumor Necrosis Factorsmedicine.diseaseInfliximabInfliximabConcomitantImmunoglobulin GImmunologyTumor Necrosis Factor InhibitorsbusinessTumor Necrosis Factorinfliximabetanercept
researchProduct

Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice

2015

International audience; Objective. The aim of this study was to evaluate the impact of introducing tocilizumab (TCZ) as co-therapy with CS in patients with RA.Methods. This study was an open, observational, retrospective multicentre study. RA patients treated with oral CS for >3 months who started treatment with TCZ between December 2009 and June 2011 in five centres were included. Variables included demographic data, disease history, co-treatments, disease activity and dose of CS at inclusion and at weeks 4, 8, 12 and 24. The evolution of disease activity and of the dose of CS (analysis of variance with repeated measures) were analysed, searching for factors correlated with changes in the …

Malerheumatoid arthritisGastroenterologycorticosteroidsArthritis Rheumatoidchemistry.chemical_compoundPrednisoneAdrenal Cortex HormonesPharmacology (medical)risksystemic glucocorticoid therapytreatmentfactor-alpha inhibitorsMiddle Aged3. Good healthClinical PracticeTreatment Outcome[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemRheumatoid arthritisAntirheumatic AgentsCorticosteroidDrug Therapy CombinationFemaleAnalysis of variancemanagementmedicine.drugAdultmedicine.medical_specialtymedicine.drug_classAntibodies Monoclonal Humanizeddiseases[ SDV.MHEP.RSOA ] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemtocilizumabTocilizumabRheumatology[SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/MedicationInternal medicinemedicineHumansIn patientbiologicsGlucocorticoidsAgedRetrospective Studiesbusiness.industry[ SDV.SP.MED ] Life Sciences [q-bio]/Pharmaceutical sciences/MedicationRepeated measures designeular recommendationsmedicine.diseaseEndocrinologychemistryPrednisonebusiness
researchProduct

Expression of the multidrug resistance glycoprotein 170 in the peripheral blood lymphocytes of rheumatoid arthritis patients. The percentage of lymph…

1996

International audience; Abstract: The objective was to evaluate the expression of the multidrug resistance P-glycoprotein (P-gp) in peripheral blood lymphocytes (PBL) of patients with rheumatoid arthritis (RA). PBL from 68 RA patients and 44 controls were evaluated. RA patients had a mean disease duration of 10.7 yr, with a mean number of past resistances to DMARDs of 0.82, and were treated with NSAIDs (n = 34), DMARDs (n = 25) and prednisolone (n = 40). Fluorescence flow cytometry was used to assess P-gp membrane expression on PBL. In the RA group, the percentage of PBL expressing P-gp was higher in patients treated with prednisolone than in other patients [mean +/- S.D.: 10.7 +/- 15.8% vs…

Malerheumatoid arthritismedicine.drug_classmedicine.medical_treatmentLymphocytePrednisolone[INFO.INFO-IM] Computer Science [cs]/Medical ImagingDrug resistanceArthritis Rheumatoidresistance03 medical and health sciences0302 clinical medicineRheumatologyImmunopathologyMDRmedicine[INFO.INFO-IM]Computer Science [cs]/Medical ImagingHumansPharmacology (medical)ATP Binding Cassette Transporter Subfamily B Member 1Lymphocytes030304 developmental biologyAgedAutoimmune disease0303 health sciencesChemotherapytreatmentglucocorticoids[ INFO.INFO-IM ] Computer Science [cs]/Medical Imagingbusiness.industryAnti-Inflammatory Agents Non-SteroidaldrugMiddle Agedmedicine.diseaseDrug Resistance Multiple3. Good healthmedicine.anatomical_structure030220 oncology & carcinogenesisRheumatoid arthritisAntirheumatic AgentsImmunologyMultivariate AnalysisPrednisoloneCorticosteroidRegression AnalysisFemalebusinessmedicine.drug
researchProduct

Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1β via the nucleot…

2015

Summary A better understanding about the mechanisms involved in the pathogenesis of type 2 diabetes mellitus (T2D) showed that inflammatory cytokines such as tumour necrosis factor (TNF) and interleukin (IL)-1β play a pivotal role, mirroring data largely reported in rheumatoid arthritis (RA). IL-1β is produced mainly by monocytes (MO), and hyperglycaemia may be able to modulate, in the cytoplasm of these cells, the assembly of a nucleotide-binding domain and leucine-rich repeat containing family pyrin (NLRP3)-inflammosome, a cytosolic multi-protein platform where the inactive pro-IL-1β is cleaved into active form, via caspase-1 activity. In this paper, we evaluated the production of IL-1 β …

Maletype 2 diabetes mellituInflammasomesMessengerIL-1β; NLRP3-inflammasome; rheumatoid arthritis; type 2 diabetes mellitus; Adult; Arthritis Rheumatoid; Carrier Proteins; Caspase 1; Cells Cultured; Diabetes Mellitus Type 2; Enzyme Activation; Female; Glucose; Humans; Hyperglycemia; Inflammasomes; Inflammation; Interleukin-1beta; Leukocytes Mononuclear; Male; Middle Aged; RNA Messenger; Tumor Necrosis Factor-alphaInterleukin-1betaArthritisPyrin domainInflammasomeArthritis RheumatoidRheumatoidImmunology and AllergyCells CulturedCulturedCaspase 1InterleukinDiabetes MellituMiddle AgedIL-1βTumor necrosis factor alphaNLRP3-inflammasomeFemalemedicine.symptomType 2ArthritiHumanAdultmedicine.medical_specialtyMononuclearImmunologyCaspase 1InflammationProinflammatory cytokineInternal medicineNLR Family Pyrin Domain-Containing 3 ProteinmedicineHumansRNA MessengerInflammationbusiness.industryTumor Necrosis Factor-alphaType 2 Diabetes MellitusOriginal Articlesrheumatoid arthritiLeukocytemedicine.diseaseEnzyme ActivationEndocrinologyGlucoseDiabetes Mellitus Type 2HyperglycemiaImmunologyLeukocytes MononuclearRNACellbusinessCarrier ProteinsCarrier Protein
researchProduct

Reliability and validity of the Finnish version of the Visual Analogue Scale Foot and Ankle (VAS-FA).

2018

Background: There have previously been no validated foot and ankle-specific patient-reported outcome measures in Finnish. Methods: The Visual Analogue Scale Foot and Ankle (VAS-FA) was translated and adapted into Finnish. Thereafter, 165 patients who had undergone foot and ankle surgery completed a questionnaire set on two separate occasions. Analyses included testing of floor-ceiling effect, internal consistency, reproducibility, and validity. Results: Minor linguistic differences emerged during the translation. Some structural adjustments were made. The mean (SD) total VAS-FA score was 74 (23). In the three subscales, maximum scores were noted in 2-5% of the responses, and internal consis…

MalevalidityVisual Analog ScalejalkaterätleikkaushoitoRESPONSIVENESSpotilaslähtöisyys0302 clinical medicineInternal consistencyHealth Status IndicatorsOrthopedics and Sports MedicineReliability (statistics)Finlandta316reliabiliteetti030222 orthopedicsOUTCOMESPain Postoperativeta3141Middle Agedmedicine.anatomical_structureFemaleVAS-FAFoot (unit)Adultmedicine.medical_specialtyPsychometricsVisual analogue scalearviointimenetelmätCULTURAL-ADAPTATIONPain03 medical and health sciencesankleEXTREMITY FUNCTIONAL SCALESCOREmedicineQUALITYHumansPatient Reported Outcome MeasuresAged030203 arthritis & rheumatologyReproducibilityreliabilitybusiness.industryFootFoot and ankle surgeryReproducibility of ResultsLower Extremity Functional ScaleINSTRUMENTSTranslating3126 Surgery anesthesiology intensive care radiologynilkathoitotuloksetfootvaliditeettiPhysical therapyAnkleAnklebusinessFoot and ankle surgery : official journal of the European Society of Foot and Ankle Surgeons
researchProduct